Dudediligence.

Replimune Group, Inc

REPLNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

84.0M

on 2026-06-30, from 61.4M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

20M40M60M80MMar2024JunSepDecMar2025JunSepDecMar2026Jun

Newest

No limit

S-3ASR of 2026-08-14. An automatic shelf: the form sets no dollar limit. None sold under it to 2026-10-05. S-3ASR ↗

9 of its filings are not read yet.

Warrants

The 10-Q filed 2026-08-14 is not read yet.

Cash

2.8 quarters

$195.3M on 2026-06-30 ÷ $69.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
DateWhatSharesPriceGrossFiling
2026-08-10Public offering incl. 2.74M pre-funded12,437,830$12.06$150.0M424B5 ↗